Evaluation of Serum Biomarkers to Inform Anemia Management in Individuals with Chronic Liver Disease
-
By
-
Yihui Rong
-
Wenpeng Fu
-
Yanyu Jiang
-
Xudong Gao
-
Jie Han
-
April 29, 2026
-
Clinical Scorecard: Evaluation of Serum Biomarkers to Inform Anemia Management in Individuals with Chronic Liver Disease
At a Glance
| Category | Detail |
|---|
| Condition | Anemia secondary to Chronic Liver Disease (CLD) |
| Key Mechanisms | Involvement of iron metabolism, erythropoietin (EPO), and inflammatory markers in anemia pathophysiology. |
| Target Population | Patients aged 15 years or older diagnosed with anemia secondary to chronic liver disease. |
| Care Setting | Hepatology department in a clinical hospital setting. |
Key Highlights
- 75% of patients with CLD are susceptible to anemia.
- Anemia in CLD is associated with disease severity and complications.
- EPO levels correlate with soluble transferrin receptor in macrocytic and normocytic anemia.
- Mean corpuscular volume (MCV) correlates with MELD and APRI scores.
- Various biomarkers show significance across different anemia types.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of anemia types should consider erythropoietin, iron metabolism markers, and inflammatory indicators.
Management
- Management of anemia may include oral and intravenous iron therapy, considering the underlying causes.
Monitoring & Follow-up
- Regular monitoring of liver function and anemia-related biomarkers is recommended.
Risks
- Risks include exacerbation of anemia due to factors like blood loss and ineffective iron therapy.
Patient & Prescribing Data
Individuals with chronic liver disease and associated anemia.
Treatment efficacy may vary due to the multifactorial nature of anemia in CLD.
Clinical Best Practices
- Utilize a panel of anemia-related biomarkers for comprehensive assessment.
- Stratify anemia management based on specific anemia subtypes and liver disease severity.
- Consider the role of inflammation and iron dysregulation in treatment planning.
References
